Gline Matthew (CIK 1750094) reported 17 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-07-02). Recent activity: Sell ROIV (76,171 shares), Sell ROIV (289,774 shares), Buy ROIV (97,319 shares), Sell ROIV (53,826 shares), Sell ROIV (304,684 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 76,171 | $2.7M |
| 2026-04-20 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 289,774 | $8.4M |
| 2026-04-01 | Roivant Sciences Ltd. (ROIV) | CEO | Buy | 97,319 | $0 |
| 2026-04-01 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 53,826 | $1.4M |
| 2026-04-01 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 304,684 | $8.4M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Buy | 234,096 | $950,430 |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 230,357 | $5.0M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 3,739 | $81,062 |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Buy | 1.4M | $17.3M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 566,116 | $12.3M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 797,595 | $17.3M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Buy | 2.3M | $28.8M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 943,527 | $20.5M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 1.3M | $28.8M |
| 2025-09-18 | Roivant Sciences Ltd. (ROIV) | CEO | Buy | 3,315 | $49,957 |
| 2025-05-22 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 10,945 | $120,833 |
| 2025-04-22 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 10,945 | $111,092 |
来源：SEC Form 4 申报文件 · 截至 2026-07-02